IP Verse

Octapharma competitive analysis

Latest oppositions filed by Octapharma

Explore patent oppositions filed by Octapharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 9, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3763384
Pharmaceutical Product With Increased Stability Comprising ImmunoglobulinsCSL BEHRINGMay 28, 2025
EP3794013
Method And System Of Protein ExtractionCSL BEHRINGNov 21, 2024
EP3226895
Pharmaceutical Product With Increased Stability Comprising ImmunoglobulinsCSL BEHRINGApr 22, 2021
EP2538975
Immunoglobulin Preparation And Storage System For An Immunoglobulin PreparationCSL BEHRINGJun 18, 2020
EP3116534
Compositions Of Human Prothrombin And Activated Factor X For Improving Hemostasis In The Treatment Of Bleeding DisordersBAXALTAFeb 28, 2020
EP2345425
Immunoglobulin G (Igg) Concentrate Depleted Of Anti-A And Anti-B Antibodies And Of Polyreactive IggsLABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESApr 11, 2019
EP2968434
C1-Inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor DeficencySHIRE VIROPHARMAMar 28, 2018

Latest patents of Octapharma opposed by its competitors

Explore Octapharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 9, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3626737
Nov 29, 2023A Method Of Increasing The Productivity Of Eucaryotic Cells In The Production Of Recombinant Fviii2
EP2707387
Dec 25, 2019A Method Of Increasing The Productivity Of Eucaryotic Cells In The Production Of Recombinant Fviii1
EP2640413
Jun 12, 2019A Process For Reduction And/Or Removal Of Fxi And Fxia From Solutions Containing Said Coagulation Factors1
EP2670429
Apr 4, 2018Method For Inactivation/Removal Of Coagulation Factors By Precipitation2
EP2825555
Jul 12, 2017Improved Process For Production Of Fibrinogen And Fibrinogen Produced Thereby2

Latest publications and patents of Octapharma New

Explore the latest publications and patents granted to Octapharma, showcasing their recent innovations and technological advancements.

Last updated on: Oct 8, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Octapharma

EP3626737
Nov 29, 2023A Method Of Increasing The Productivity Of Eucaryotic Cells In The Production Of Recombinant FviiiGranted And Under Opposition
EP2707387
Dec 25, 2019A Method Of Increasing The Productivity Of Eucaryotic Cells In The Production Of Recombinant FviiiRevoked
EP2640413
Jun 12, 2019A Process For Reduction And/Or Removal Of Fxi And Fxia From Solutions Containing Said Coagulation FactorsOpposition Rejected
EP2670429
Apr 4, 2018Method For Inactivation/Removal Of Coagulation Factors By PrecipitationRevoked
EP2825555
Jul 12, 2017Improved Process For Production Of Fibrinogen And Fibrinogen Produced TherebyRevoked

Latest PTAB cases involving Octapharma

Discover the latest PTAB cases involving Octapharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Octapharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 9, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
OCTAPHARMA78 - -
BIOTEST5 - - -
CSL BEHRING394 -
STRAWMAN333 - - -